JPS6028826B2 - Method for producing benzylamine derivatives - Google Patents

Method for producing benzylamine derivatives

Info

Publication number
JPS6028826B2
JPS6028826B2 JP49133281A JP13328174A JPS6028826B2 JP S6028826 B2 JPS6028826 B2 JP S6028826B2 JP 49133281 A JP49133281 A JP 49133281A JP 13328174 A JP13328174 A JP 13328174A JP S6028826 B2 JPS6028826 B2 JP S6028826B2
Authority
JP
Japan
Prior art keywords
group
piverazine
reaction
compound
melting point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP49133281A
Other languages
Japanese (ja)
Other versions
JPS5159884A (en
Inventor
敏弘 石黒
安 三野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP49133281A priority Critical patent/JPS6028826B2/en
Priority to DE19752551355 priority patent/DE2551355A1/en
Priority to GB4724075A priority patent/GB1477088A/en
Priority to NL7513425A priority patent/NL7513425A/en
Priority to BE161968A priority patent/BE835689A/en
Priority to FR7535204A priority patent/FR2291757A1/en
Priority to CA239,892A priority patent/CA1074311A/en
Priority to ES442762A priority patent/ES442762A1/en
Publication of JPS5159884A publication Critical patent/JPS5159884A/ja
Priority to US05/793,356 priority patent/US4091220A/en
Priority to US05/882,891 priority patent/US4153794A/en
Publication of JPS6028826B2 publication Critical patent/JPS6028826B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は、医薬として有用な一般式(1)〔式中、R1
、R2は同一または異なって、水素原子、低級アルキル
カルボニル基またはペンゾィル基を示し、R3は水素原
子、置換基として水酸基、フェニル基あるいはモルホリ
ノカルボニル基を有していてもよい低級アルキルまたは
低級アルケニル基、置換基としてメルカプトあるいはモ
リホリノ基を有していてもよい低級アルキルカルボニル
基またはペンゾィル基を示す。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides compounds of the general formula (1) [wherein R1
, R2 are the same or different and represent a hydrogen atom, a lower alkylcarbonyl group or a penzoyl group, and R3 is a hydrogen atom, a lower alkyl or lower alkenyl group which may have a hydroxyl group, phenyl group or morpholinocarbonyl group as a substituent. , represents a lower alkylcarbonyl group or a penzoyl group which may have a mercapto or morpholino group as a substituent.

×はハロゲン原子を示す〕で表わされるペンジルフミン
誘導体の製造法に関する。さらに詳しくは、本発明は一
般式(0) 〔式中、R1,R2およびR3は前記と同意義〕で表わ
される化合物をハロゲン化することを特徴とする一般式
(1)のペンジルアミン譲導体の製造法に関する。
x indicates a halogen atom] The present invention relates to a method for producing a penzylphumine derivative represented by the following. More specifically, the present invention provides a pendylamine derivative of general formula (1), which is characterized by halogenating a compound represented by general formula (0) [wherein R1, R2 and R3 have the same meanings as above]. Regarding manufacturing methods.

前記各式中、RIおよびR2で示される低級アルキルカ
ルボニル基としては、たとえばアセチル,プロピオニル
,プチリル基などの、そのアルキル部分が炭素数1〜3
程度の低級ァルキル基である低級ァルキルカルボニル基
があげられる。
In each of the above formulas, the lower alkylcarbonyl group represented by RI and R2 is an alkyl group having 1 to 3 carbon atoms, such as acetyl, propionyl, butyryl group, etc.
Examples include lower alkylcarbonyl groups, which are lower alkyl groups.

R3で示される低級アルキル基または低級アルケニル基
としては、たとえば、メチル,エチル,プロピル,イソ
フ。ロピル,ブチル,イソブチル,tertーブチル,
sec−ブチル,アリル,ベンチル,ヘキシル基などの
炭素数1〜6程度の直鎖、分枝状のものがあげられる。
これらの基が、そ置換暦としてさらに水素基、フェニル
基またはモルホリノカルボニル基を有している場合、こ
れらの置換基は1または2個以上R3で示される基の任
意の位置に置換していてよい。置換基がフェニル基の場
合のフェニル置換アルキルとしては、たとえばベルジル
,フェネチル基などのアラルキル基があげられる。R3
で示される低級アルキル基が置換基として水酸基を有す
る場合、これらの置換基の具体例としては、たとえば、
ヒド。キシメチル’B−ヒド。キシエチル,ツ−ヒドロ
キシプロピルなどのヒドロキシアルキル基があげられる
。R3で示される低級アルキルカルボニルとしては、R
1,R2で示されるのと同様のアルキル部分が炭素数1
〜3程度の低級アルキル基であるアルキルカルボニル基
があげられる。R3で示される低級アルキルカルボニル
基が、その置換基としてさらにメルカプトまたはモルホ
リノ基を有している場合、これらの置換基は1〜2個以
上R3で示される低級アルキルカルボニル基の任意の位
置に置換していてよい。これらの置換基を有する低級ア
ルキルカルボニル基の具体例としては、たとえばメルカ
プトアセチル,8−〆ルカプトプロピオニルなどのメル
カプトアシル,モリホリノアセチル,8ーモルホリノプ
ロピオニルなどがあげられる。×で示されるハロゲン原
子は、塩素、臭素、ヨウ素およびフッ素原子であり、な
かでも臭素、塩素原子の場合が好ましい。本発明の方法
は、一般式(ロ)の化合物とハロゲン化剤とを反応させ
ることにより行われる。
Examples of the lower alkyl group or lower alkenyl group represented by R3 include methyl, ethyl, propyl, and isof. Lopyl, butyl, isobutyl, tert-butyl,
Examples include straight chain and branched groups having about 1 to 6 carbon atoms, such as sec-butyl, allyl, bentyl, and hexyl groups.
When these groups further have a hydrogen group, phenyl group or morpholinocarbonyl group as a substituent, one or more of these substituents may be substituted at any position of the group represented by R3. good. Examples of the phenyl-substituted alkyl when the substituent is a phenyl group include aralkyl groups such as verzyl and phenethyl groups. R3
When the lower alkyl group represented by has a hydroxyl group as a substituent, specific examples of these substituents include, for example,
Hide. oxymethyl'B-hydro. Examples include hydroxyalkyl groups such as xyethyl and dihydroxypropyl. The lower alkylcarbonyl represented by R3 is R
1, the same alkyl moiety as shown in R2 has 1 carbon number
An example is an alkylcarbonyl group which is a lower alkyl group of about 3 to 30%. When the lower alkylcarbonyl group represented by R3 further has a mercapto or morpholino group as a substituent, one to two or more of these substituents may be substituted at any position of the lower alkylcarbonyl group represented by R3. It's okay to do so. Specific examples of lower alkylcarbonyl groups having these substituents include mercaptoacetyl, mercaptoacyl such as 8-lcaptopropionyl, morpholinoacetyl, 8-morpholinopropionyl, and the like. The halogen atoms indicated by x are chlorine, bromine, iodine and fluorine atoms, with bromine and chlorine atoms being particularly preferred. The method of the present invention is carried out by reacting the compound of general formula (b) with a halogenating agent.

反応に使用し得るハロゲン化剤としては、芳香環のハロ
ゲン化反応に使用し得るものをいずれも使用でき、たと
えば、塩素、臭素等のハロゲン自体、臭化ナトリウムと
塩素とより製するブロムクロラィド(Br+CI‐)、
塩化ナトリウムと臭素より製するクロルフロマィド(C
rBr)などがあげられる。反応は通常、不活性溶媒中
で行われる。反応に使用される不活性溶剤としては、例
えば、ベンゼン,トルェン等の芳香族炭化水素のほか、
石油ベンジン,n−へキサン等および例えば、四塩化炭
素,クロロホルム,ジクロルメタン等のハ。ゲン化炭化
水素さらに、たとえば、酢酸、プロピオン酸等の有機カ
ルボン酸があげられる。反応溶媒としては、なかでも有
機カルポン酸、ハロゲン化炭化水素が好ましい。反応温
度としては通常約一200 から約140『0までの温
度を適宜使用し得るが、とりわけ室温下で有利に反応を
行うことができる。ハロゲン化剤の使用量は原料化合物
(0)1モルに対し、通常約2モルから約20モル当量
程度であるが、化合物(ロ)1モルに対し、2モル当量
、或いはその僅かな過剰分を使用するのが好ましい。目
的化合物(1)は、遊離の形または使用したハロゲン化
剤に対応するハロゲン化水素酸塩として生成するが、い
ずれも、たとえばクロマトグラフィー蒸留或いは再結晶
など常法に依って精製される。このようにして得られる
目的化合物(1)が遊離塩基の場合生理学的に許容され
る無機或いは有機酸を用いて公知方法たとえば、当該酸
のアルコール溶液を化合物(1)の1〜3モル当量と反
応させることにより、対応する酸付加塩に変換すること
ができる。酸としては、たとえば塩酸、臭化水素酸、硫
酸、リン酸などの無機酸のほか、乳酸、クエン酸、酒石
酸、マレイン酸等の有機酸があげられる。なお、本発明
の目的化合物(1)は、次に式示される合成法によって
も製造することができる。
As the halogenating agent that can be used in the reaction, any one that can be used in the halogenation reaction of aromatic rings can be used. For example, halogen itself such as chlorine and bromine, bromochloride (Br+CI -),
Chlorfuromide (C
rBr), etc. The reaction is usually carried out in an inert solvent. Examples of inert solvents used in the reaction include aromatic hydrocarbons such as benzene and toluene;
Petroleum benzine, n-hexane, etc. and, for example, carbon tetrachloride, chloroform, dichloromethane, etc. Examples of the hydrogenated hydrocarbons include organic carboxylic acids such as acetic acid and propionic acid. Among these, organic carboxylic acids and halogenated hydrocarbons are preferred as the reaction solvent. As the reaction temperature, a temperature of about 1,200 to about 140° can be used as appropriate, but the reaction can be particularly advantageously carried out at room temperature. The amount of halogenating agent used is usually about 2 to about 20 molar equivalents per 1 mol of starting compound (0), but 2 mol equivalents or a slight excess thereof per 1 mol of compound (B). It is preferable to use The target compound (1) is produced in a free form or as a hydrohalide salt corresponding to the halogenating agent used, and both are purified by conventional methods such as chromatographic distillation or recrystallization. When the target compound (1) obtained in this way is a free base, a known method using a physiologically acceptable inorganic or organic acid, for example, an alcoholic solution of the acid is mixed with 1 to 3 molar equivalents of the compound (1). By reacting, it can be converted into the corresponding acid addition salt. Examples of acids include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, as well as organic acids such as lactic acid, citric acid, tartaric acid, and maleic acid. In addition, the object compound (1) of the present invention can also be produced by the synthesis method shown by the following formula.

〔式中、R3およびXは前記と同意義〕本工程のニトロ
基還元反応は、後述の本発明の出発化合物(0)の製造
の際の工程(B)における化合物(c)の還元反応と同
じ条件で行なわれる。
[In the formula, R3 and carried out under the same conditions.

〔式中、R1,R2,R3およびXは前記と同意義〕本
工程のケトン基の還元は鍔化金属ハイドライドによる還
元で製造される。
[In the formula, R1, R2, R3 and X have the same meanings as above.] The ketone group in this step is reduced by reduction with a fluorinated metal hydride.

たとえば、リチウムアルミニウムハイドライド,ナトリ
ウムアルミニウムハイドライド,ナトリウムボロンハイ
ドライドなどが挙げられ、溶媒としては、エーテル’テ
トラヒドロフランジオキサンなどのエーテル類、ベンゼ
ン,nーヘキサンなどの炭化水素類など、反応を阻害し
ないものなら使用できる。また温度は、一5〜120q
oまで、で実施される。〔式中、R1,R2,R3およ
びXは前記と同意義〕本工程の脱水反応は脂肪酸の存在
下、更に詳しくは、酢酸、プロピオン酸青草酸などの存
在下無溶媒としてはキシレン,テトラリンなどを用いて
もよい。
Examples include lithium aluminum hydride, sodium aluminum hydride, sodium boron hydride, etc. As a solvent, anything that does not inhibit the reaction can be used, such as ethers such as ether'tetrahydrofuran dioxane, and hydrocarbons such as benzene and n-hexane. . Also, the temperature is between 15 and 120q.
It is carried out until o. [In the formula, R1, R2, R3 and may also be used.

この混合物を120〜200qoに加熱することにより
、化合物(1)を製造することができる。〔式中、R1
,R2,R3および×は前記と同意義、RI′およびR
2′はR1,R2で示されるのと同様の低級ァルキルカ
ルボニル基またはペンゾィル基を示す〕本工程のアシル
化反応は、後述の本発明の出発化合物(ロ)の製造の際
の工程(B)における化合物(0′)のアシル化反応と
同じ条件で行われる。
Compound (1) can be produced by heating this mixture to 120 to 200 qo. [In the formula, R1
, R2, R3 and × have the same meanings as above, RI' and R
2' represents the same lower alkylcarbonyl group or penzoyl group as shown by R1 and R2] The acylation reaction in this step is carried out in the step (B) in the production of the starting compound (b) of the present invention, which will be described later. ) is carried out under the same conditions as the acylation reaction of compound (0').

〔式中、R1,R2,および×は前記と同意義、世1は
塩素,臭素などのハロゲン原子を示し、R3′はR3の
定義から水素原子を除いたものを示す〕本工程の置換反
応はR3′−也1で表わされるハラィドを出発化合物(
ロ)と反応させ、(1)を得る方法で、溶媒としては、
アルコール類,ケトン類,炭化水素類及び、ハロゲン炭
化水素,ジメチルホルムアルデヒドが挙げられ、反応温
度は0〜120qoで実施される。
[In the formula, R1, R2, and × have the same meanings as above, 1 represents a halogen atom such as chlorine or bromine, and R3' represents the definition of R3 excluding a hydrogen atom] Substitution reaction of this step is a starting compound (
b) to obtain (1), the solvent is:
Examples include alcohols, ketones, hydrocarbons, halogen hydrocarbons, and dimethyl formaldehyde, and the reaction temperature is 0 to 120 qo.

またR3′一也1は、(ロ)に対して、通常当モル量も
しくは、わずかに過剰分が用いられる。本発明の方法に
ついて従って製造される目的化合物(1)またはその塩
は、気道液分泌促進作用,抗ヒスタミン作用および/ま
たは抗塵鰹作用を有する新規化合物であり、気道液分泌
促進剤(去漆剤)、抗ヒスタミン剤または抗産鰹剤等の
医薬として用いることができる。
Furthermore, R3' Kazuya1 is usually used in an equimolar amount or in a slightly excess amount relative to (b). The target compound (1) or a salt thereof produced according to the method of the present invention is a novel compound having respiratory tract fluid secretion promoting action, antihistamine action and/or anti-dust bonito action, and is an airway fluid secretion promoting agent (removal of lacquer). It can be used as a medicine such as an antihistamine agent or an anti-salt bonito agent.

化合物(1)またはその塩をこれらの医薬として用いる
場合、薬学的に許蓉し得る希釈剤、迫体、賦形剤、溶解
剤と.章多混合し、錠剤、カプセル剤、散剤、額粒剤、
水剤、シロップ剤、エアゾール剤、軟膏、注射剤、坐剤
等の種々の剤形で経口または非経口的に投与することが
できる。このうち、化合物(1)の酸付加塩は水に可溶
であり、特に注射剤、水剤として用いるのに好的である
。化合物(1)またはその塩の投与量は、対象疾患、化
合物の種類等によって異なるが、前記の医薬として用い
る場合、成人常用量として約5〜200のo/日である
。なお、本発明の原料化合物(0)は、たとえば、ジヤ
ーナル・オブ・ケミカルソサエテイ(JomMi of
ChemicalSociety)1722頁(19船
年)に記載の方法に従って、下記に式次される工程によ
っても製造することができる。〔式中、R1,R2,R
3は前記と同意義、X′は×と同様のハロゲン原子を示
す〕化合物【b)‘ま、ジャーナル・オブ・ケミカルソ
サエテイ(JoumalofChemicalSoci
ety)39頁(192鱗王)に記載の方法またはこれ
に準ずる方法に従って製造することができる。
When compound (1) or a salt thereof is used as a pharmaceutical for these purposes, a pharmaceutically acceptable diluent, excipient, excipient, solubilizing agent, etc. Mixed with chapters, tablets, capsules, powders, granules,
It can be administered orally or parenterally in various dosage forms such as solutions, syrups, aerosols, ointments, injections, and suppositories. Among these, the acid addition salt of compound (1) is soluble in water and is particularly suitable for use as an injection or aqueous solution. The dosage of compound (1) or a salt thereof varies depending on the target disease, the type of compound, etc., but when used as the above-mentioned medicine, the usual dose for adults is about 5 to 200 o/day. Note that the raw material compound (0) of the present invention is, for example, available from Journal of Chemical Society (JomMi of
It can also be produced according to the method described in Chemical Society), p. 1722 (19th year), and by the steps shown below. [In the formula, R1, R2, R
3 has the same meaning as above, and X' represents a halogen atom similar to
ety) page 39 (192 Uroko) or a method analogous thereto.

工程凶の反応は化合物a’と化合物{b)を反応させる
ことにより行われ、化合物‘b}の使用量は、化合物(
a’1モルに対し、通常約1〜3モル当量程度である。
The reaction in the process is carried out by reacting compound a' and compound {b), and the amount of compound 'b} used is the same as that of compound (
It is usually about 1 to 3 molar equivalents per mol of a'.

反応は通常溶媒中で行われ、溶媒としては、たとえばア
ルコール類(例、メタノール,エタノール,プロパノー
ル)、ハロゲン化炭化水素類(例、四塩化炭素,クロロ
ホルム,ジクロルメタン)、ケトン類(例、アセトン,
メチルエチルケトン)、ジメチルホルムアルデヒド等が
あげられる。反応温度は通常0〜120qoの温度で適
宜行われ、溶媒を用いる場合は通常使用する溶媒の沸点
付近である。工程‘B’の反応は、まず工程凶で得られ
る化合物‘c}を還元することにより行われる。
The reaction is usually carried out in a solvent, such as alcohols (e.g. methanol, ethanol, propanol), halogenated hydrocarbons (e.g. carbon tetrachloride, chloroform, dichloromethane), ketones (e.g. acetone,
Methyl ethyl ketone), dimethyl formaldehyde, etc. The reaction temperature is usually 0 to 120 qo, and when a solvent is used, it is around the boiling point of the solvent. The reaction in step 'B' is carried out by first reducing the compound 'c' obtained in the process.

反応に用いられる還元剤は、芳香環のニトロ基をアミノ
基に還元し得るものあればいずれも用いることができ、
たとえば、ラネニツケル,酸化白金,パラジウム炭素な
どの触媒存在下で接触還元;水硫化ナトリウムを用いる
還元;ラネニツケルーヒドラチンヒドラートを用いる還
元などがあげられる。反応条件は、用いる還元剤によっ
て異なる。接触還元では、通常、室温で反応が進行し、
水硫化ナトリウムを用いる還元では、溶媒として用いる
アルコール(例、メタノール,エタノール,プロパノー
ル)等の沸点付近で行なわれる。ラネーニッケルーヒド
ラチソヒドラートを用いる反応では、通常溶媒として、
前記のアルコール等を用いて行われるが反応それ自体、
発熱反応であり、加熱の必要はない。好ましくは約50
〜70o○で、反応が実施される。一般式(0)におい
て、RIおよび/またはR2が低級アルキルカルボニル
またはペンゾイル基の化合物(ロ″)は、前述の工程‘
B}の還元反応によって得られる2ーアミノベンジルピ
ベラジン誘導体(0′)〔式中、R3は前記と同意義) の2位のアミ/基のアシル化によって製造される。
Any reducing agent used in the reaction can be used as long as it can reduce the nitro group of the aromatic ring to an amino group.
Examples include catalytic reduction in the presence of a catalyst such as Ranenitzker, platinum oxide, palladium on carbon, etc.; reduction using sodium hydrogen sulfide; and reduction using Ranenitzker-hydratine hydrate. Reaction conditions vary depending on the reducing agent used. In catalytic reduction, the reaction usually proceeds at room temperature,
Reduction using sodium hydrosulfide is carried out near the boiling point of the alcohol (eg, methanol, ethanol, propanol) used as a solvent. In reactions using Raney nickel hydratisohydrate, the solvent is usually
Although the reaction itself is carried out using the above-mentioned alcohol, etc.
It is an exothermic reaction and does not require heating. Preferably about 50
The reaction is carried out at ˜70°. In the general formula (0), the compound (ro'') in which RI and/or R2 are lower alkylcarbonyl or penzoyl groups is
2-aminobenzylpiverazine derivative (0') (wherein R3 has the same meaning as above) obtained by the reduction reaction of B} is produced by acylation of the amine/group at the 2-position.

アシル化反応は、2−アミノベンジルピベラジン誘導体
(ロ′)とアシル化剤とを反応させることにより行われ
、アシル化剤としては、R1,R2で示される低級アル
キルカルボニル基またはペンゾィル基に対応する低級脂
肪族または芳香族カルボン酸の反応性談導体(例、アセ
チルクロリド,ベンゾイルクロリド等の酸ハライド,無
水酢酸,無水安息香酸等の酸無水物、これらの酸の混合
酸無水物)があげられる。アシル化剤の使用量は、化合
物(ロ′)1モルに対し、通常約1〜4モル当量程度で
ある。反応は通常溶媒中で行われ、溶媒としては、たと
えば酢酸エチル,酢酸ブチル等のェステル類,テトラヒ
ドロフラン,ジオキサン等のエーテル類があげられる。
反応温度は通常約oo 〜12000程度である。かく
して得られる2一(モノアシルアミノ)一または2一(
ジアシルアミノ)−ペンジルピベラジン誘導体(ロ″)
は、このモノーまたはジアシルアミノ基のァシル基(低
級アルキルカルボニル基またはペンゾイル基)の1個、
又は両方を所望により常方たとえば塩酸、硫酸、リン酸
等の鱗酸を用いる加水分解方法で脱離せしめることがで
き、逆に2−(モノアシルアミノ)−ペンジルピベラジ
ン誘導体(0″)は、さらに前記のアシル化反応を行っ
て、2一(ジアシルアミノ)ーベンジルピベラジン誘導
体(0″)に導くことができる。
The acylation reaction is carried out by reacting the 2-aminobenzylpiverazine derivative (2') with an acylating agent. The corresponding reactive conductors of lower aliphatic or aromatic carboxylic acids (e.g., acid halides such as acetyl chloride and benzoyl chloride, acid anhydrides such as acetic anhydride and benzoic anhydride, and mixed acid anhydrides of these acids) can give. The amount of the acylating agent used is usually about 1 to 4 molar equivalents per 1 mol of compound (b'). The reaction is usually carried out in a solvent, and examples of the solvent include esters such as ethyl acetate and butyl acetate, and ethers such as tetrahydrofuran and dioxane.
The reaction temperature is usually about 0 to 12,000 ℃. The thus obtained 21(monoacylamino)1 or 21(
diacylamino)-penzylpiverazine derivative (RO'')
is one of the acyl groups (lower alkylcarbonyl group or penzoyl group) of this mono or diacylamino group,
Or, if desired, both can be removed by a conventional hydrolysis method using scale acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc., and conversely, 2-(monoacylamino)-penzylpiverazine derivative (0'') can be further subjected to the above-mentioned acylation reaction to lead to the 2-(diacylamino)-benzylpiverazine derivative (0'').

以下、実施例により本発明を更に詳細に説明する。Hereinafter, the present invention will be explained in more detail with reference to Examples.

実施例 1 N,ーメチルーN4−(2ーアミノー3,5−ジプロム
ベンジル)ピベラジン塩酸塩酢酸10の上にN,ーメチ
ルーN4一(2ーアミノベンジル)ピベラジン0.81
0夕をとかし、よく櫨杵下、これに0.320夕のブロ
ムを室温下加え、30分間反応させる。
Example 1 N,-methyl-N4-(2-amino-3,5-dipromobenzyl)piverazine hydrochloride acetic acid 10 on top of N,-methyl-N4-(2-aminobenzyl)piverazine 0.81
Dissolve the 0.32% bromine in a pestle, add 0.32% bromine at room temperature, and allow to react for 30 minutes.

ついで反応液から減圧下、溶媒を蟹去し、得られる残留
物を濃アンモニア水でアルカリ性とし、クロロホルムで
抽出する。クロロホルム層を無水硫酸ナトリウムで乾燥
し、クロロホルムを留去する。得られる油状物を18%
エタノール−塩酸処理し得られる結晶性物質をメタノー
ルから再結晶すると淡黄色晶が得られる。融点 182
〜185q C 分析値 C,2日,7N3Br2・HC1・日20理論
値 C 34.51:日 4.82:N IO.06実
験値 C 34.42;日 5.31:N 9.75実
施例 2実施例1と同様にして、対応するアミノベンジ
ルピベラジン誘導体からそれぞれ次の化合物が得られる
Then, the solvent is removed from the reaction solution under reduced pressure, and the resulting residue is made alkaline with concentrated aqueous ammonia and extracted with chloroform. The chloroform layer is dried over anhydrous sodium sulfate, and the chloroform is distilled off. 18% of the resulting oil
When the crystalline substance obtained by the ethanol-hydrochloric acid treatment is recrystallized from methanol, pale yellow crystals are obtained. Melting point 182
~185q C Analytical value C, 2 days, 7N3Br2・HC1・day 20 Theoretical value C 34.51: day 4.82: N IO. 06 Experimental value C 34.42; Sun 5.31:N 9.75 Example 2 In the same manner as in Example 1, the following compounds are obtained from the corresponding aminobenzylpiverazine derivatives.

N,−水素−N4一(2ーアミノー3,5ージブロムベ
ンジル)ピベラジン塩酸塩(融点 194〜19600
)、N,一n−プロピル−N4−(2ーアミノー3,5
ージブロムベンジル)ピベラジン塩酸塩(融点 167
〜16900)、N,一ペンジル−N4一(2−アミノ
−3,5−ジブロムベンジル)ーピベラジン塩酸塩(融
点 215〜220午C)、N,一〔(モルフオリノー
カルボニル)ーメチル〕一N4−(2−アミノ−3,5
−ジブロムベンジル)−ピベラジン臭化水素酸塩(融点
201〜204oo)、N,一(8−ハイドロキシエ
チル)−N4−(2−アミノー3,5−ジブロムベンジ
ル)ピベラジン塩酸塩(融点 148〜150午○)、
N,一〔(モルフオリノーメチル)−力ルボニル〕−N
4一(2−アミノー3,5−ジブロムベンジル)ピベラ
ジン塩酸塩(融点 224〜227q0)、N,ーィソ
プロピル−N4一(2−アミノ−3,5−ジブロムベン
ジル)ピベラジン塩酸塩(融点 205〜20900)
、N,ーメルカプトアセチル一N4−(2ーアミノー3
,5ージフロムベンジル)ピベラジン塩酸塩(融点 1
82〜18600(分解))、N,一アセチル−N4一
(2ージアセチルアミノ−3,5ージブロムベンジル)
ピベラジン塩酸塩(融点 140〜14yo)、N,一
ペンゾイル−N4一(2−モノベンゾイルアミノ一3,
5ージブロムベンジル)ピベラジン塩酸塩(融点 15
3〜155o0)、N,一シンナミィル−N4−(2−
アミノ−3,5−ジブロムベンジル)ピベラジン塩酸塩
(融点 208〜210qo(分解))N.一(モルホ
リノカルボニルメチル)−N4一(2−ジアセチルアミ
ノー3,5−ジブロムベンジル)ピベラジン塩酸塩(融
点163〜165o0)、N,一(モルホリノカルポニ
ルメチル)−N4(2’ーモノベンゾイルアミノー3,
5ージブロムベンジル)ピベラジン塩酸塩(融点162
〜164℃)、N,一(モルホリノカルボニルエチル)
一N4一(2−アミノー3,5ージブロムベンジル)ピ
ベラジン塩酸塩(融点150〜154二○(分解))参
考例 1 {1) N,ーメチルーN4−(2ーニトロベンジル)
ピベラジンの製造0ーニトロベンジルクロライド2.1
6夕をエタノール20の【に溶解し、ついでこれにN−
メチルピベラジン1.02夕及び炭酸カリ1・3夕を加
え、1時間、還流下反応させる。
N,-Hydrogen-N4-(2-amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 194-19600
), N,1n-propyl-N4-(2-amino-3,5
-dibromobenzyl)piverazine hydrochloride (melting point 167
~16900), N,1penzyl-N4-(2-amino-3,5-dibromobenzyl)-piverazine hydrochloride (melting point 215-220°C), N,1[(morpholinocarbonyl)-methyl]-N4 -(2-amino-3,5
-dibromobenzyl)-piverazine hydrobromide (melting point 201~204oo), N,1(8-hydroxyethyl)-N4-(2-amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 148~ 150pm ○),
N,1[(morpholinomethyl)-carbonyl]-N
4-(2-amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 224-227q0), N,-isopropyl-N4-(2-amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 205-227q0) 20900)
, N,-mercaptoacetyl-N4-(2-amino-3
,5-difurobenzyl)piverazine hydrochloride (melting point 1
82-18600 (decomposition)), N,1-acetyl-N4-(2-diacetylamino-3,5-dibromobenzyl)
Piverazine hydrochloride (melting point 140-14yo), N,1penzoyl-N4-(2-monobenzoylamino-3,
5-dibromobenzyl)piverazine hydrochloride (melting point 15
3-155o0), N,-cinnamyl-N4-(2-
Amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 208-210qo (decomposed)) N. -(morpholinocarbonylmethyl)-N4-(2-diacetylamino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 163-165o0), N,1(morpholinocarbonylmethyl)-N4(2'-monobenzoyl) Minnow 3,
5-dibromobenzyl)piverazine hydrochloride (melting point 162
~164℃), N,1 (morpholinocarbonylethyl)
-N4-(2-amino-3,5-dibromobenzyl)piverazine hydrochloride (melting point 150-154 2○ (decomposition)) Reference example 1 {1) N,-methyl-N4-(2-nitrobenzyl)
Manufacture of Piverazine 0 Nitrobenzyl chloride 2.1
Dissolve 60% of ethanol in 20% of ethanol, and then add N- to this.
Add 1.02 hours of methylpiverazine and 1.3 hours of potassium carbonate, and react under reflux for 1 hour.

ついで反応液を炉遇し、母液から減圧下溶媒を留去し、
得られる残留物を水ーェーテル(1:1)で抽出する。
エーテル層を分取し、無水流酸ナトリウムで乾燥し、溶
媒を留去すると褐色油状物が得られる。赤外線吸収スペ
クトル(液状フィルム)肌‐1:1610,1538。
核磁気共鳴スペクトル(重クロロホルム)ppm:2.
25(細,1車線),2.40(4日,1重線),3.
73(2日,1重線),7.2〜7.9(岬,多重線)
(2) N,ーメチルーN4一(2ーアミノベンジル)
ピベラジンの製造N,ーメチル−N4(2ーニトロベン
ジル)−ピベラジン1.87夕をエタノール30の‘に
溶かし、ついでこれにラネニツケル3.0夕を加える。
Then, the reaction solution was heated in a furnace, and the solvent was distilled off from the mother liquor under reduced pressure.
The resulting residue is extracted with water-ether (1:1).
The ether layer is separated, dried over anhydrous sodium sulfate, and the solvent is distilled off to obtain a brown oil. Infrared absorption spectrum (liquid film) skin-1:1610,1538.
Nuclear magnetic resonance spectrum (deuterochloroform) ppm: 2.
25 (narrow, 1 lane), 2.40 (4 days, 1 double line), 3.
73 (2nd, single line), 7.2-7.9 (cape, multiple line)
(2) N,-methyl-N4-(2-aminobenzyl)
Preparation of Piverazine 1.87 g of N,-methyl-N4(2-nitrobenzyl)-piverazine is dissolved in 30 g of ethanol and then 3.0 g of Lanenickel is added thereto.

これに、さらにヒドラチンヒドラート3.0夕を加え室
温下、2時間反応させる。反応後、反応混合物からフネ
ーニッケルを炉別し、母液から減圧下落煤を留去し得ら
れる油状物を含水メタノールから再結晶すると淡黄色晶
が得られる。融点 78〜7900元素分析 C,2日
,ぶ3理論値 C 70.20;日 9.33;N 2
0.47実験値 C 70.01;日 9.69:N
20.40参考例 2参考例1と同様にして0ーニトロ
ベンジルクロラィドとピべへラシンまたは対応するN−
置換ピベラジン誘導体から、それぞれ次の化合物が得ら
れる。
To this, 3.0 g of hydratine hydrate was further added and reacted at room temperature for 2 hours. After the reaction, Fune nickel is separated from the reaction mixture in a furnace, soot is distilled off from the mother liquor under reduced pressure, and the resulting oil is recrystallized from water-containing methanol to obtain pale yellow crystals. Melting point 78-7900 Elemental analysis C, 2 days, bu 3 Theoretical value C 70.20; days 9.33; N 2
0.47 Experimental value C 70.01; Sun 9.69:N
20.40 Reference Example 2 In the same manner as in Reference Example 1, nitrobenzyl chloride and pibeheracin or the corresponding N-
The following compounds can be obtained from the substituted piperazine derivatives.

N,一水素一N4一(2ーアミノベンジル)ピベラジン
(融点 127〜128qo),N.−nープロピルー
N4一(2ーアミノベンジル)ピベラジン塩酸塩(融点
215〜220℃),N,−ペンジルーN4一(2−
アミノベンジル)ピベラジン(融点 92〜93q○)
,N,一〔((モルフオリノーカルボニル)−メチル〕
−N4(2−アミノベンジル)ーピベラジン(融点 1
58〜160℃),N,一(8−ハイドロキシエチル)
一N4−(2ーアミノベンジル)−ピベラジン・マレイ
ン酸塩(融点 152〜153℃),N.ーシンナミイ
ルーN4−(2ーアミノベンジル)ーピベラジン(融点
185〜187℃),N,一イソプロピル−N4一(
2ーアミ/ペンジル)ーピベラジン油状物。
N, monohydrogen-N4-(2-aminobenzyl)piverazine (melting point 127-128qo), N. -n-propyl-N4-(2-aminobenzyl)piverazine hydrochloride (melting point 215-220°C), N,-penzyl-N4-(2-
aminobenzyl) piperazine (melting point 92-93q○)
,N,1 [((morpholinocarbonyl)-methyl]
-N4(2-aminobenzyl)-piverazine (melting point 1
58-160℃), N,1(8-hydroxyethyl)
-N4-(2-aminobenzyl)-piverazine maleate (melting point 152-153°C), N. -Cinnamyl-N4-(2-aminobenzyl)-piverazine (melting point 185-187°C), N,1-isopropyl-N4-(
2-ami/penzyl)-piverazine oil.

核磁気共鳴吸収スペクトル(重クロロホルム)肌:1.
03(餌,2重線 J=7),2.50(知日,1車線
),2.舷(IH,2車線J=7),3.46(が,1
車線),6.4〜7.2(岬,多重線)N,一(モルホ
リノメチルカルボニル)一N4一(2−アミノベンジル
)ピベラジン,油状物。
Nuclear magnetic resonance absorption spectrum (deuterochloroform) skin: 1.
03 (Bait, double line J=7), 2.50 (Chichi, 1 lane), 2. Ship (IH, 2 lanes J=7), 3.46 (but, 1
lane), 6.4-7.2 (cape, multiplet) N, one (morpholinomethylcarbonyl) one N4 one (2-aminobenzyl) piperazine, oil.

核磁気共鳴吸収スペクトル(NMR)(重クロロホルム
)跡:2.3〜2.8(母日,多重線).3.20(班
,1車線),3.43(が,1車線),3.4〜3.9
(母日,多重線),5.0(が),6.4〜7.2(4
日,多重線),N,一(メルカプトメチルカルボニル)
一N4−(2−アミノベンジル)ピベラジン,熱晶形物
。NM凪(重クロロホルム)肌:2.1〜2.7(4日
,多重線),3.3〜3.9((』日,多重線),3.
43(2日,1重線),3.50(斑,1垂線).6.
5〜7.4(4日,多重線)N,一(モルホリノカルボ
ニルエチル)一N4−(2ーアミノベンジル)ピベラジ
ン(融点 65〜670〇)
‐参考例 3N.−(モルホリノカルボニ
ルメチル)−N4−(2ーアミノベンジル)ピベラジン
100爪9のピリジン3の.【溶液にペンゾィルクロリ
ド62の9を加え、室温で一夜放置する。
Nuclear magnetic resonance absorption spectrum (NMR) (deuterochloroform) trace: 2.3 to 2.8 (mother's day, multiplet). 3.20 (group, 1 lane), 3.43 (but, 1 lane), 3.4-3.9
(Mother's Day, multiplet), 5.0 (ga), 6.4-7.2 (4
day, multiplet), N, one (mercaptomethylcarbonyl)
-N4-(2-aminobenzyl)piverazine, hot crystal form. NM Nagi (heavy chloroform) skin: 2.1-2.7 (4 days, multiplet), 3.3-3.9 ((''day, multiplet), 3.
43 (2 days, single line), 3.50 (spot, 1 perpendicular line). 6.
5-7.4 (4 days, multiplet) N,1(morpholinocarbonylethyl)-N4-(2-aminobenzyl)piverazine (melting point 65-670〇)
- Reference example 3N. -(morpholinocarbonylmethyl)-N4-(2-aminobenzyl)piverazine 100 nails 9 pyridine 3. [Add 9 of penzoyl chloride 62 to the solution and leave it at room temperature overnight.

ついでピリジンを減圧下に蟹去し、残留物を酢酸エチル
を用いたシリカゲルカラムクロマトグラフイーに付すと
油状物として、N,一(モルホリノカルボニルメチル)
−N4一(2ーモノベンゾイルアミノベンジル)ピベラ
ジンが得られる。NMR(重クロロホルム)柳:2.4
0(岬,1垂線),2.80(4日,1重線),3.0
3,3.18(各IH,ブロード1重線),3.53(
斑,1重線),3.60(8日,ブロード1車線),6
.8〜8.3■日,多重線)。同様の方法で、対応する
2−アミノベンジルピベラジン誘導体とアシル化剤とか
ら、次の化合物が得られる。
Then, the pyridine was removed under reduced pressure, and the residue was subjected to silica gel column chromatography using ethyl acetate to obtain N,1(morpholinocarbonylmethyl) as an oil.
-N4-(2-monobenzoylaminobenzyl)piverazine is obtained. NMR (heavy chloroform) Yanagi: 2.4
0 (cape, 1 perpendicular), 2.80 (4 days, 1 double line), 3.0
3, 3.18 (each IH, broad single line), 3.53 (
Spotted, single line), 3.60 (8th, Broad 1 lane), 6
.. 8-8.3 ■ days, multiplet). In a similar manner, the following compound is obtained from the corresponding 2-aminobenzylpiverazine derivative and an acylating agent.

N,一(モルホリノカルボニルメチル)−N4一(2ー
ジアセチルアミノベンジル)ーピベラジン,油状物。
N,1(morpholinocarbonylmethyl)-N4-(2-diacetylaminobenzyl)-piverazine, oil.

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ 〔式中、R^1、R^2は同一または異なつて水素原
子、低級アルキルカルボニル基またはベンゾイル基を示
し、R^3は水素原子、置換基として水換基、フエニル
基あるいはモルホリノカルボニル基を有していてもよい
低級アルキルまたは低級アルケニル基、置換基としてメ
ルカプトあるいはモルホリノ基を有していてもよい低級
アルキルカルボニル基またはベンゾイル基を示す〕で表
わされる化合物をハロゲン化することを特徴とする一般
式▲数式、化学式、表等があります▼ 〔式中、R^1
、R^2およびR^3は前記と同意義、Xはハロゲン原
子を示す〕で表わされるベンジルアミン誘導体の製造法
[Claims] 1 General formula▲ Numerical formula, chemical formula, table, etc.▼ [In the formula, R^1 and R^2 are the same or different and represent a hydrogen atom, a lower alkylcarbonyl group, or a benzoyl group, and R^ 3 is a hydrogen atom, a lower alkyl or lower alkenyl group which may have a hydration group, phenyl group or morpholinocarbonyl group as a substituent, a lower alkylcarbonyl group which may have a mercapto or morpholino group as a substituent or a benzoyl group] is characterized by halogenating a compound ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ [In the formula, R^1
, R^2 and R^3 have the same meanings as above, and X represents a halogen atom].
JP49133281A 1974-11-19 1974-11-19 Method for producing benzylamine derivatives Expired JPS6028826B2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP49133281A JPS6028826B2 (en) 1974-11-19 1974-11-19 Method for producing benzylamine derivatives
DE19752551355 DE2551355A1 (en) 1974-11-19 1975-11-15 N-BENZYLPIPERAZINE
GB4724075A GB1477088A (en) 1974-11-19 1975-11-17 N-benzylpiperazines
NL7513425A NL7513425A (en) 1974-11-19 1975-11-17 PROCESS FOR THE PREPARATION OF NEW BENZYLAMINE DERIVATIVES.
FR7535204A FR2291757A1 (en) 1974-11-19 1975-11-18 N-BENZYLPIPERAZINES
BE161968A BE835689A (en) 1974-11-19 1975-11-18 N-BENZYLPIPERAZINES
CA239,892A CA1074311A (en) 1974-11-19 1975-11-18 N-benzlpiperazines
ES442762A ES442762A1 (en) 1974-11-19 1975-11-18 N-benzylpiperazines
US05/793,356 US4091220A (en) 1974-11-19 1977-05-03 Morpholinocarbonyl alkyl N-benzylpiperazines
US05/882,891 US4153794A (en) 1974-11-19 1978-03-01 N-Benzylpiperazines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP49133281A JPS6028826B2 (en) 1974-11-19 1974-11-19 Method for producing benzylamine derivatives

Publications (2)

Publication Number Publication Date
JPS5159884A JPS5159884A (en) 1976-05-25
JPS6028826B2 true JPS6028826B2 (en) 1985-07-06

Family

ID=15100960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP49133281A Expired JPS6028826B2 (en) 1974-11-19 1974-11-19 Method for producing benzylamine derivatives

Country Status (8)

Country Link
JP (1) JPS6028826B2 (en)
BE (1) BE835689A (en)
CA (1) CA1074311A (en)
DE (1) DE2551355A1 (en)
ES (1) ES442762A1 (en)
FR (1) FR2291757A1 (en)
GB (1) GB1477088A (en)
NL (1) NL7513425A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618677A (en) * 1984-05-31 1986-10-21 Boehringer Ingelheim Limited Substituted phenylalkyl-(piperazinyl or homopiperazinyl)alkyl-thiols and -thiocarbamates useful for the treatment of immunological, inflammatory, and allergic disorders
US4722926A (en) * 1984-11-05 1988-02-02 Boehringer Ingelheim Limited Substituted phenylalkyl-(piperazinyl or homopiperazinyl)alkyl thiols and thiocarbamates useful for the treatment of immunological, inflammatory, and allergic disorders
US6124299A (en) * 1997-02-24 2000-09-26 Zymogenetics, Inc. Calcitonin mimetics
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions

Also Published As

Publication number Publication date
JPS5159884A (en) 1976-05-25
GB1477088A (en) 1977-06-22
FR2291757B1 (en) 1979-09-21
CA1074311A (en) 1980-03-25
NL7513425A (en) 1976-05-21
FR2291757A1 (en) 1976-06-18
ES442762A1 (en) 1977-04-16
BE835689A (en) 1976-05-18
DE2551355A1 (en) 1976-05-20

Similar Documents

Publication Publication Date Title
US4675319A (en) Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use
JPS6056143B2 (en) Amidine derivatives and their production method
JPS6028826B2 (en) Method for producing benzylamine derivatives
JPS6047255B2 (en) Process for producing 2-amino-5-sulfamoyl-benzoic acid amide
JPS60202872A (en) Benzofuran derivative, its preparation, and hypotensive agent containing said derivative as active component
CA1083588A (en) Xanthene-9-carboxylates and a process for the preparation thereof
JPS6354363A (en) Quinoline derivative
US2759942A (en) Substituted piperidinecarboxylates and methods of preparing same
US4153794A (en) N-Benzylpiperazines
KR850001040B1 (en) Process for preparing allophanoylpiperazine compounds
US4438133A (en) Therapeutically effective derivatives of cystine
JPS60231634A (en) Biphenyloxyaminoalkanes and medicine
US3974282A (en) Hypoglycemic stilbazolte derivatives
JPH06507387A (en) Novel ureas and thioureas, their production and therapeutic applications
JP2678768B2 (en) Tetrahydroimidazo [2,1-b] benzothiazole derivative and antiulcer agent containing the compound as an active ingredient
US4091220A (en) Morpholinocarbonyl alkyl N-benzylpiperazines
JPS5993050A (en) Preparation of carbostyril derivative
HU215916B (en) Substituted n-aminoalkylmetane sulfanilide as antispasmodica, pharmaceutical compositions comprising them and process for producing thereof
JPH0357896B2 (en)
JPS6160673A (en) Preparation of guanidinothiazole derivative
JPH0296542A (en) Benzocycloheptene derivative
KR800000537B1 (en) Process for the preparation of amin-pheny-etahnolamines
JPH04283567A (en) Novel compound, medicinal composition containing the novel compound and process for producing same
JPS61227578A (en) 1,3-dioxa-2-thiane-2-oxide derivative and its production
JPS5995286A (en) Imidazo(4,5-c)pyridine-6-carboxylic acid derivative